Simon To, M.B.A., Executive Director and Chairman, Hutchison China MediTech Limited
Christian Hogg, M.B.A., Executive Director and Chief Executive Officer, Hutchison China MediTech Limited
Weiguo Su, Ph.D., Executive Director and Chief Scientific Officer, Hutchison China MediTech Limited
Ye Hua, MD, MPH, Senior Vice President, Head of Clinical Development & Regulatory Affairs
Zhenping Wu, Ph.D., M.B.A., Senior Vice President, Pharmaceutical Sciences
May Wang, Ph.D., Senior Vice President, Business Development & Strategic Alliances
Mark Lee, M.B.A., Senior Vice President, Corporate Finance and Development
Hong Chen, E.M.B.A., Chief Commercial Officer – China
Marek Kania, MD, M.B.A., Chief Medical Officer – US
Yang Sai, Ph.D., Senior Vice President, Head of Drug Metabolism and Pharmacokinetics
Xiong Li, Ph.D., Senior Vice President, Head of Inflammation & Immunology
Weiguo Qing, Ph.D., Senior Vice President, Head of Oncology Research
Enrico Magnanelli, M.B.A., Vice President, Head of International Operations
Mr. To has been a Director since 2000 and an Executive Director and Chairman of the Company since 2006. He is also the Chairman of the Remuneration Committee and a member of the Technical Committee of the Company. He is managing director of Hutchison Whampoa (China) Limited (“Hutchison China”) and has been with Hutchison China for over 37 years, building its business from a small trading company to a multi-billion dollar investment group. He has negotiated major transactions with multinationals such as Procter & Gamble (“P&G”), Lockheed, Pirelli, Beiersdorf, United Airlines and British Airways. He is currently a director of Gama Aviation Plc.
Mr. To’s career in China spans more than 37 years. He is the original founder of Hutchison Whampoa Limited’s (currently a subsidiary of CK Hutchison Holdings Limited (“CKHH”)) China healthcare business and has been instrumental in the acquisitions made to date. He received a First Class Honors Bachelor’s Degree in Mechanical Engineering from Imperial College, London and an MBA from Stanford University’s Graduate School of Business (graduated top 5% of his class).
Mr. Hogg has been an Executive Director and Chief Executive Officer since 2006. He is also a member of the Technical Committee of the Company. He joined Hutchison Whampoa (China) Limited in 2000 and has since led all aspects of the creation, implementation and management of the Company’s strategy, business and listing. This includes the creation of the Company’s start-up businesses and the acquisition and operational integration of assets that led to the formation of the Company’s China joint ventures.
Prior to joining Hutchison China, Mr. Hogg spent ten years with Procter & Gamble starting in the United States in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr. Hogg then moved to China to manage P&G’s detergent business followed by a move to Brussels to run P&G’s global bleach business. Mr. Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and an MBA from the University of Tennessee.
Dr. Su has been an Executive Director of the Company since March 27, 2017. He is also a member of the Technical Committee of the Company. He has been the Executive Vice President and Chief Scientific Officer of the Company since 2012. Dr. Su has headed all drug discovery and research since he joined the Company, including master-minding the Company’s scientific strategy, being a key leader of the Innovation Platform, and responsible for the discovery of each and every small molecule drug candidate in the Company’s product pipeline. Prior to joining the Company in 2005, Dr. Su spent 15 years with the U.S. Research and Development Department of Pfizer, Inc. with his last position as director of the Medicinal Chemistry Department.
In March 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.
Dr. Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai. He completed a PhD and Post-doctoral Fellowship in Chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.
Dr. Hua leads and manages the clinical organization and oversees the development programmes that are being developed in different indications.
Prior to joining the company in 2014 with over 16 years of global new drug development and registration experience, Dr. Hua had worked in Global Clinical Development as Senior Director and Medical Director at Celgene and Novartis, respectively. He led Phase II and III registration trials in oncology, hematology, osteoarthritis, osteoporosis, and infectious disease. As clinical lead, Dr. Hua contributed to the regulatory approval and life-cycle management for Reclast/Aclasta, Prexige, Zometa, Femara, Proleukin and Cardioxane in the US and EU. More recently, at Celgene he led several teams for Revlimid and Pomalyst global development in multiple myeloma, and successfully obtained Revlimid regulatory approval in multiple myeloma in China.
Dr. Hua received a Bachelor’s of Medicine from Fudan University Shanghai Medical College, and a Master’s degree in epidemiology from McGill University in Canada.
Dr. Wu heads all non-clinical development at the company, focusing on the CMC development and manufacturing of the Company’s pipeline. The Pharmaceutical Sciences department is responsible for process research, API & drug product manufacture, analytical R&D, quality control, supply chain management, CMC regulatory affairs, pilot plant development, and managing third party contractors. Dr Wu has over 22 years of experience in drug discovery and development.
Prior to joining HMP in 2008, Dr Wu held several leadership positions, including Senior Director of Pharmaceutical Sciences at Phenomix, a California biotech company; Director of Pharmaceutical Development at Pfizer Global R&D in San Diego (formerly Agouron); and group leader at Roche in Palo Alto. Dr. Wu has led many teams and advanced numerous candidates through different phases of clinical development and commercialization, such as the blockbuster anti-cancer drug Sutent.
Dr. Wu received a Ph. D. degree from Hong Kong University, and an MBA degree from the University of California at Irvine. He is the past Chairman and President of the Board of the Sino-American Biotechnology and Pharmaceutical Association. He received a Dean’s Scholar Award from the University of California at Irvine, a Leadership Award from the Sino-American Biotechnology and Pharmaceutical Association, and an American Heart Association Fellowship.
Dr. Wang heads all alliance management and business development for the company. She has been instrumental in engaging with, negotiating, executing and very actively liaising with all our development partners, including AstraZeneca, Nestlé Health Science, and Eli Lilly.
Prior to joining HMP in 2010, Dr. Wang spent 16 years with Eli Lilly and was the Head for Asian Biology Research, responsible for establishing and managing research collaborations in China and Pan-Asia. Dr. Wang has broad drug discovery and development experience spanning several therapeutic areas including infectious diseases, inflammation and oncology. She was a co-inventor for several drug candidates including the blockbuster drug INCIVEK (telaprevir, LY570310) launched in 2011 for treatment of HCV infection.
Dr. Wang has numerous patents, published more than 50 peer-reviewed articles and has given dozens of seminars and plenary lectures. She received her Ph.D. in Biology from Purdue University, USA.
Mr. Lee focuses on HMP’s strategic management, corporate operations, investor relations and supporting its numerous R&D alliances. This includes leading or assisting with the project management of certain clinical programmes, coordination of R&D leadership, and R&D financial management.
Prior to joining the company in 2009, Mr. Lee was with Credit Suisse in the United States and Europe, where he was involved in the execution and origination of mergers, acquisitions, public and private financings, and corporate strategy for pharmaceutical, life science and healthcare companies such as AstraZeneca, Bristol-Myers Squibb, Genzyme and Syngenta, amongst others.
Mr Lee received his Bachelor of Engineering in Biochemical Engineering with First Class Honours from University College London, where he was awarded a Dean’s Commendation. He also received a Master of Business Administration from the Massachusetts Institute of Technology, Sloan School of Management.
Mr. Chen holds and has held several key senior management roles at Chi-Med, spearheading many of our businesses within our Commercial Platform. When he initially joined Chi-Med he was the Deputy General Manager of Hutchison Baiyunshan, overseeing the manufacture, marketing and distribution of our proprietary OTC drug products. In 2012, he assumed the parallel role of General Manager of Hutchison Healthcare, which focuses on health supplements. In 2014, he stepped down from Hutchison Baiyunshan to become the General Manager of the newly-formed Hutchison Sinopharm business, focusing on providing marketing, distribution and logistics services for prescription drugs manufactured by third parties.
In 2018, Mr. Chen was promoted to the role of Chi-Med – Chief Commercial Officer – China, and will be responsible for the establishment of both government affairs and commercial organizations within our Innovation Platform. He will retain his current responsibilities for Hutchison Sinopharm and Hutchison Healthcare.
Prior to joining Chi-Med in 2011, Mr. Chen spent twelve years with Bristol-Myers Squibb starting from a Product Manager and becoming its National Sales & Marketing Director in China.
Mr. Chen received a Bachelor’s degree in Medicine from Nanjing Medical University, China and an EMBA from Cheung Kong Graduate School of Business.
Dr. Kania had spent 25 years with Lilly, leading teams on several oncology products, including Erbitux®, Alimta® and Gemzar®, around the world, with experience that includes clinical research and development; oncology product development; global medical affairs including product launches; and medical policy and strategy. Dr. Kania joined Lilly in 1993 after practicing as an anesthesiologist and critical care physician.
Dr. Kania is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Kania received his medical training at the Silesian School of Medicine in Katowice, Poland, and subsequently completed an anesthesiology and critical-care residency, with board certification from Jagiellonian University School of Medicine in Krakow. Dr. Kania also holds an MBA degree from The University of Chicago Booth Graduate School of Business.
Dr. Sai has headed the drug metabolism, pharmacokinetics (DMPK) and drug safety evaluation teams since he established them in 2006. He leads these teams to process clinical pharmacology/pharmacokinetic studies for drug discovery and development.
Dr. Sai spent 21 years at the Beijing Institute of Radiation Medicine, the National Institutes of Health, the University of Washington and Harvard University; and over 11 years of industrial experience, all in DMPK, pharmacology and safety evaluation. Immediately prior to joining in 2006, he was Principal Scientist at Neurocrine Biosciences.
Dr. Sai earned his B.S. in pharmacy from the 2nd Military Medical University, his M.S. in pharmacology and toxicology from the Beijing Institute of Radiation Medicine, and earned his Ph.D. in biopharmacy from King’s College London, London University.
Dr. Li heads autoimmune disease and gastroenterology research, pursuing novel small molecule and botanical drug candidates. He also coordinates the project management of certain drug programmes in clinical development.
Dr. Li joined the company in 2012 after 12 years with Pfizer and two years with GSK. During his tenure at Pfizer, He made great contributions to Pfizer’s JAK program with its lead compound, Tofacitinib, approved by US FDA in 2012. In 2010, Dr. Li joined GSK China, heading up research in neuro-inflammation area mainly in multiple sclerosis. Dr. Li has in-depth and first-hand experience and expertise in major areas of inflammation and immunology, including rheumatoid arthritis, multiple sclerosis and COPD.
Dr. Li earned his BS and MS in Chemistry from Nankai University and Shanghai Jiao Tong University, respectively, and a Ph. D. degree in Pharmacology from University of North Carolina at Chapel Hill. In addition, he pursued his post-doctoral training at Lineberger Comprehensive Cancer Center, UNC.
Dr. Qing oversees all oncology related projects, as well as organising the handling and planning the Company’s oncology portfolio, oncology research budgeting and general operations.
Dr. Qing joined the Company in 2008 with 11 years in drug discovery and development at Roche and Abbott and over 20 years in oncology, as well as experience in inflammatory disease. He spent 6 years at Roche in US, during which he was a lead or core team member for multiple key projects, including moving the MDM-2 project from early preclinical stage to Phase I, and selecting a new target for further research.
Dr. Qing did his postdoctoral research at University of Illinois at Chicago, and received his Ph. D. from the University of Texas MD Anderson Cancer Center-University of Texas at Austin. He received his Master’s degree from Institute of Materia Medica, Chinese Academy of Medical Sciences, and Bachelor of Science in Pharmacy from the College of Pharmacy, Beijing University. Dr. Qing has published over 33 papers and meeting abstracts and is sole inventor for one issued US patent.
Mr. Magnanelli focuses on establishing and expanding our operations outside of China, including working towards commercial launches outside of mainland China.
Prior to joining the company in 2018, he spent over 12 years with Gilead Sciences in commercial roles across Europe and Asia, most recently as Head, Inflammation and New Therapy Areas Business Unit, EMEA. Prior to this role, he was involved in the launch of the hepatitis franchise in Japan and the establishment of new operations across several European countries and Asia. Prior to Gilead Sciences, Mr. Magnanelli was at Eli Lilly in Italy where he held roles in market research and marketing working in different therapeutic areas including oncology, CNS and ED.
Mr. Magnanelli received his degree in Business and Economics from the University of Genova and his Masters of Business Administration from the MIB School of Management.